Closed Loop Medicine secures patents for cardiometabolic therapies

Closed Loop Medicine Ltd. has announced that it has received key patents from the US Patent Office. These patents focus on advancements in treatments for obesity and diabetes using GLP-1 therapies, as well as for cardiovascular health with direct oral anticoagulants (DOACs). With these new patents, Closed Loop Medicine aims to strengthen its cardiometabolic treatment portfolio. The company now holds over 65 patent filings across 16 families, which supports its mission to offer precision medicine solutions. The newly granted intellectual property allows for personalized dosing in GLP-1 therapies. This means treatments can be tailored based on individual patient needs, such as their level of exercise or calorie intake. This approach can help patients stick to their weight management plans and improve health outcomes. Additionally, the latest patent extends its capabilities into DOAC therapy. This will help provide more personalized and effective treatments to prevent strokes and other cardiovascular issues. The company is focused on using AI technology to enhance these treatments and ensure safety and effectiveness. Dr. Hakim Yadi, CEO of Closed Loop Medicine, emphasized the importance of this patent portfolio for leadership in AI-enabled personalized medicine. The patents will enable better clinical outcomes and optimize treatments for complex health issues.